Experiencia de un hospital universitario en el manejo de púrpura trombótico trombocitopénico-microangiopatía trombótica no inmune refractaria o en recaída tratado con rituximab: Report of eight cases / Treatment of thrombotic thrombocytopenic purpura with rituximab
Rev. méd. Chile
;
143(6): 809-811, jun. 2015. tab
Article
in Spanish
| LILACS
| ID: lil-753523
ABSTRACT
Thrombotic thrombocytopenic purpura, an immune/non-immune thrombotic microangiopathy (TTP/TMA) is associated with high morbidity and mortality, even with appropriate treatment. In patients refractory to standard treatment with plasmapheresis there is no certainty about the best therapeutic strategy. This report shows our experience in eight refractory patients who survived after treatment with rituximab.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Purpura, Thrombotic Thrombocytopenic
/
Rituximab
Type of study:
Observational study
/
Risk factors
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
Spanish
Journal:
Rev. méd. Chile
Journal subject:
Medicine
Year:
2015
Type:
Article
Affiliation country:
Chile
Institution/Affiliation country:
Pontificia Universidad Católica de Chile/CL
Similar
MEDLINE
...
LILACS
LIS